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Today many patients admitted with an acute coronary syndrome 
are already taking aspirin. Because they have symptoms despite 
antithrombotic therapy, these patients are presumed to be at 
higher risk for subsequent clinical events. In a pilot trial of 
antithrombotic therapy in patients with unstable angina at rest or 
non-Q wave infarction, 93 patients admitted within 48 h of pain 
were prospectively followed up for 12 weeks. On admission, 29 
patients (31%) were already taking daily aspirin; 64 (68%) were 
receiving no antiplatelet agent. After enrollment all patients 
received antithrombotic therapy with either aspirin or heparin 
according to protocol regardless of prior aspirin use. 
The two groups (prior users versus nonusers of aspirin) were 
similar with regard to age, gender, coronary risk factors, prior 
antianginal medication, duration of symptomatic coronary dis-
ease, presentation with non-Q wave infarction and extent of 
electrocardiographic changes on admission. Quantitative analysis 
Several large scale clinical trials (1-5) have delineated the 
natural history of patients presenting with unstable angina 
and the beneficial effect of antithrombotic therapy in this 
syndrome. However, by design, all of these investigations 
excluded patients who were using a platelet inhibitor before 
enrollment. Recently it has become apparent that many 
patients presenting with the acute coronary syndrome of 
unstable angina or non-Q wave myocardial infarction are 
already using aspirin as an antithrombotic agent (6). Thus, 
the question arises, Are patients using aspirin who experi-
ence myocardial ischemia at a higher risk for subsequent 
clinical events than are patients with ischemia who were not 
taking aspirin? 
The aim of this study was to compare the demographic, 
clinical and angiographic characteristics of patients present-
ing with unstable angina or non-Q wave infarction during 
aspirin use with those of patients admitted during the same 
time period without prior aspirin use. In addition, both 
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of coronary arteriograms (on a 0 to 10 scale) showed similar 
myocardium-in-jeopardy scores (JS). Follow-up events (recurrent 
ischemia [lsch], infarction [MI] and revascularization [Revasc]) 
were: 















Aspirin users experiencing rest angina are similar to other 
patients with ischemic rest pain. The "resistant to aspirin" group 
does not constitute a subgroup that is at higher risk for cardiac 
events or revascularization. 
(JAm Coli Cardio/1991;18:1458-62) 
groups were prospectively followed up for 12 weeks, allow-
ing comparison of their subsequent cardiac event rates. 
Methods 
Patient selection. The study group was derived from 94 
patients presenting with non-Q wave myocardial infarction 
or angina pectoris at rest who were enrolled in our prospec-
tive trial (6) of antithrombotic therapy in the acute coronary 
syndromes and who were followed up for 3 months. This 
study was conducted at Mount Sinai Hospital after approval 
by the Institutional Review Board concerned with human 
research. From March 1987 to March 1989, all patients with 
cardiac pain, chest pain at rest or non-Q wave infarction 
were screened. Men and women between the ages of 21 and 
75 years were eligible if they met both of the following 
inclusion criteria: 
1. On hospital admission they had ischemic pain caused 
by unstable angina or non-Q wave infarction defined as 
a) recent onset (<4 weeks) of prolonged (~10 min) or 
recurrent (~2 episodes/day) chest pain suggesting acute 
myocardial ischemia; b) chest pain occurring at rest or with 
minimal effort and with no provoking factors; and c) chest 
pain occurring within 48 h of screening. 
2. In addition, there must have been clinical evidence of 
underlying ischemic heart disease, as shown by at least one 
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of the following: a) electrocardiographic (ECG) changes 
during chest pain (T wave changes, 2: 1 mm ST segment 
depression) or transient ST segment elevation; b) prior 
history of myocardial infarction, positive findings on an 
exercise test or a coronary arteriogram; or c) typical effort-
related chest pain relieved by rest or nitroglycerin, or both. 
Exclusion criteria were evolving Q wave myocardial 
infarction; left bundle branch block; angina precipitated by 
obvious provoking factors (such as heart failure, tachyar-
rhythmia, hypertension [systolic blood pressure 2:160, dias-
tolic blood pressure 2:100 mm Hg]); current use of or 
contraindications to anticoagulation; coronary angioplasty 
within 6 months or coronary bypass surgery within 1 year; or 
inability or unwillingness of the patient to give consent. 
Specifically, current aspirin users were not excluded from 
enrollment. 
Study groups. After consent was obtained, the 94 pa-
tients were randomized to one of three antithrombotic regi-
mens including aspirin or heparin, or both, added to conven-
tional antianginal medication (6). Of the 94 patients enrolled, 
1 patient signed out from the emergency room against 
medical advice and was not included in this analysis. In three 
other patients, in-hospital follow-up was complete but long-
term follow-up was not available. These 3 patients, with a 
complete in-hospital follow-up study, together with the 
remaining 90 patients, constitute the study group. On admis-
sion, 29 patients (31%) were taking aspirin daily or had 
ingested ::::325 mg within the preceding 4 days. The other 64 
patients (69%) were not receiving any antiplatelet agent. The 
94 patients originally enrolled constituted 54% of the 174 
patients eligible for the study (6). 
Study protocol. Regardless of prior aspirin use, patients 
were randomized to one of three therapies: l) aspirin alone, 
325 mg daily; 2) heparin + warfarin alone (full dose of 
intravenous heparin for 3 to 5 days followed by warfarin to 
maintain the prothrombin time at 1.5 to 2 x control); or 
3) aspirin and heparin + warfarin (aspirin, 80 mg daily, plus 
heparin followed by warfarin, as in treatment 2). In addition 
to the trial therapy, all patients received standard antianginal 
therapy with nitrates plus a beta-adrenergic blocking agent 
or a calcium channel blocking agent, or both. The doses of 
the three antianginal drugs were maximized within 48 h of 
admission to reduce the systolic blood pressure to ::::; 120 to 
130 mm Hg and the heart rate to ::s65 beats/min. Use of 
aspirin containing medication other than the trial drugs was 
prohibited. Trial therapy and study end points were moni-
tored daily during the hospital stay. After discharge, patients 
were reevaluated at 6 and 12 weeks with use of the interval 
history, any readmission hospital records, 12 lead electro-
cardiogram and hematocrit determinations. 
Coronary arteriographic analysis. Fifty-eight of the 93 
patients underwent cardiac catheterization and coronary 
arteriography 4 ± 3 days after admission: 19 (66%) of the 29 
patients who had used aspirin before admission and 39 (61%) 
of the 64 who had not. In these 58 patients the extent of 
myocardium in jeopardy was quantified by assignment of a 
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jeopardy score based on the severity of coronary artery 
disease according to the method of Califf et al. (7). The 
severity of coronary artery stenoses was assessed in multiple 
views. A stenosis of the left main coronary artery was 
considered clinically significant if there was ::::50% narrow-
ing of the luminal diameter; for all other arteries, ::::70% 
narrowing was required to establish significance. The myo-
cardium-in-jeopardy score ranged from 0 to 10 and was 
based on the number of vessels with significant stenoses and 
the location of the stenoses (proximal or distal). Grade 1 = 
stenosis in a distal left anterior descending artery or first 
diagonal branch or in a nondominant left circumflex artery 
beyond the first obtuse marginal branch, or distal right 
coronary artery beyond the origin of the posterior descend-
ing artery or narrowing within the posterior descending 
artery. Grade 2 = stenosis in the mid-right coronary artery 
or a nondominant circumflex artery proximal to the first 
obtuse marginal branch or within a large first obtuse mar-
ginal branch. Grade 3 = stenosis in the proximal dominant 
right coronary artery or mid-left anterior descending coro-
nary artery. Grade 5 = stenosis in the proximal left anterior 
descending artery (before the first septal perforator). Grade 
7 = left main artery stenosis. A dominant circumflex artery 
stenosis was considered equal to a right coronary artery 
stenosis. In multivessel disease grades were added arithmet-
ically. Grade 0 = no significant stenoses. 
Morphology of the culprit lesion. Six of the 58 arterio-
grams revealed nonobstructive coronary artery disease. In 
43 arteriograms the ischemia-producing vessel and the cul-
prit lesion were identifiable and amenable to an analysis of 
stenosis morphology. Fifteen arteriograms were from pa-
tients who had used aspirin before admission and 28 were 
from patients who had not. With use of the criteria of 
Ambrose eta!. (8), the stenosis precipitating the acute onset 
of symptoms was characterized as 1) ulcerated versus 
smooth, 2) with or without a discrete intraluminal filling 
defect suggesting thrombus, and 3) eccentric versus concen-
tric. 
Unfavorable outcome. Unfavorable outcome in the hos-
pital phase or during the 12-week follow-up period was 
defined as follows: l) Recurrent myocardial ischemia (recur-
rent angina at rest with ischemic ECG changes). 2) Myocar-
dial infarction (chest pain associated with new ST-T wave 
changes or Q waves and a rise in serum creatine kinase 
levels to more than two times the upper limit of normal). In 
patients admitted with a non-Q wave infarction, reinfarction 
was diagnosed by recurrent pain associated with new ST-T 
wave changes or Q waves and an increase in creatine kinase 
activity that was ::::50% over the level in the preceding 
sample and 2: 1.5 times the upper limit of normal (9). Perio-
perative myocardial infarction was identified by a combina-
tion of ECG and enzyme criteria; the creatine kinase MB 
fraction had to be >50 mU/ml (normal value <16 mU/ml). 
3) Death (all deaths regardless of etiology occurring during 
the 12 week follow-up period). 4) Revascularization with 
coronary angioplasty or bypass surgery for recurrent pain or 
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Table 1. Clinical Characteristics of the Study Patients 
Prior Aspirin Use 
Total 
Yes No Group 
(n = 29) (n = 64) (n = 93) 
Demographics 
Age (mean, yr) 63 ± 8 61 ± 9 62 ± 9 
Male gender 22 (76%) 34 (53%)* 56 (60%) 
Previous MI ll (38%) 17 (27%) 28 (30%) 
Cigarette smoker 17 (59%) 34 (53%) 51 (55%) 
Systemic hypertension 13 (45%) 33 (51%) 46 (49%) 
Diabetes mellitus 6 (21%) 28 (44%)* 34 (37%) 
Medication before admission 28 (96%) 52 (81%)* 80 (86%) 
Interval from onset of angina 49 ± 68 46 ± 65 47 ± 66 
or first MI (mo) 
Interval from onset of change in 15 ± 19 ll ± 13 13 ± 17 
pattern of angina (days) 
In-hospital data 
Non-Q wave infarction on 12 (41%) 22 (34%) 34 (37%) 
admission 
ST-T changes at randomization 20 (69%) 47 (73%) 67 (72%) 
ECG leads with changes 5 ± 3 5 ± 3 5 ± 3 
Underwent coronary 19 (66%) 39 (61%) 58 (62%) 
arteriography 
Vessels with > 70% stenosis 2.1 ± l 2.2 ± l 2.1 ± l 
JS-70 3.7 ± 2.6 3.9 ± 3.3 3.8 ± 3 
JS-90 2.7 ± 2.5 2.8 ± 3 2.7 ± 2.8 
*Difference between the groups with and without prior aspirin in use is 
significant (p < 0.05). JS = 70, JS = 90 =myocardium in jeopardy score using 
2:70% or 2:90% stenoses; MI = myocardial infarction: ECG leads with 
changes = number of electrocardiographic leads with ST segment or T wave 
changes. 
compelling anatomic indications (2::90% stenosis in the prox-
imal segment of either the left anterior descending, dominant 
left circumflex or right coronary artery). Angioplasty or 
bypass surgery in the absence of these indications was not 
considered an unfavorable outcome. 
The following additional outcomes were also tabulated: 
1) recurrent chest pain with or without acute ECG changes; 
and 2) major bleeding defined as bleeding requiring transfu-
sion of 2::2 U of blood or corrective surgery, or both, or 
resulting in death, disability or intracranial or retroperitoneal 
hemorrhage. After coronary bypass surgery, a requirement 
of transfusion of > 2 U of blood was considered major 
bleeding. 
Statistical analysis. Continuous variables are presented 
as mean values ± SD. Clinical variables were compared 
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using the Student's t test or chi-square analysis. A p value< 
0.05 was considered significant. 
Results 
Characteristics of the study population group (Table 1). 
The total study group (n = 93) consisted of patients who 
were at high risk for coronary artery disease. More than two 
thirds had at least one coronary risk factor before admission 
and 84% had either a prior myocardial infarction or a history 
of stable angina. Fifty-nine patients presented with unstable 
angina and 34 with a non-Q wave infarction. At the time of 
admission, 29 (31%) of the 93 patients were taking aspirin on 
a daily basis and 64 patients (69%) were not. The patients 
with prior aspirin use were equally distributed among the 
three antithrombotic treatment regimens. 
Demographics. Comparison of baseline demographic 
characteristics of patients who did or did not use aspirin 
before admission revealed only a few significant differences 
(Table 1). Prior aspirin users were more likely to be male, 
nondiabetic and already receiving antianginal medication. 
Extent of coronary artery disease and culprit lesion mor-
phology (Table 2). With regard to clinical and arteriographic 
data acquired after hospital admission, no significant differ-
ences were observed between patients who did or did not 
use aspirin before admission. Specifically, both the extent of 
ischemic ECG changes on admission and the extent of 
arteriographically documented coronary artery disease were 
similar for the two groups. Morphologic analysis of the 
culprit lesion revealed that the majority of lesions in both 
groups of patients were ulcerated and eccentric, and there 
was no difference in the frequency of intraluminal thrombus. 
Unfavorable outcome (Table 3). An unfavorable outcome 
(that is, defined as recurrent myocardial ischemia, infarc-
tion, death or revascularization with coronary angioplasty or 
bypass surgery for recurrent pain or compelling anatomic 
indications) occurred in 56 (62%) of the 93 patients during 
the 3-month follow-up period. No significant differences 
were observed between the two groups in relation to recur-
rent myocardial ischemia, myocardial infarction or death. 
Recurrent ischemia occurred at a mean of 3 ± 2 days after 
admission for the group as a whole (n = 93) and was similar 
for prior aspirin users and nonusers. With regard to the 
secondary end points of recurrent chest pain (with or with-
out ECG changes) or revascularization (with coronary an-
Table 2. Angiographic Morphology of the Culprit Lesion in 43 Patients* 
Ulcerated Eccentric Intraluminal Thrombus Total Occlusion 
Yes No Yes No Yes No Yes No 
Prior aspirin use II 4 12 3 3 12 14 
(n = 15) (73%) (27%) (80%) (20%) (20%) (80%) (7%) (93%) 
No prior aspirin use 19 9 25 3 4 24 2 26 
(n = 28) (68%) (32%) (89%) (II%) (14%) (86%) (7%) (93%) 
*There were 43 cases amenable to an angiographic morphologic analysis. 
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Table 3. Unfavorable Outcomes in 93 Patients 
Prior Aspirin Use 
Yes No 
(n = 29) (n = 64) 
Primary end points 
Recurrent ischemia (pain + ECG) 8 (27%) 21 (33%) 
Myocardial infarction (total) I (3%) 3 (5%) 
Perioperative infarction 0 2 (3%) 
Death 0 I (2%) 
Secondary end points 
Recurrent chest pain 16 (55%) 33 (52%) 
PICA orCABG 13 (44%) 33 (52%) 
Major bleeding during trial therapy 0 0 
Major bleeding while not receiving 3 (10%) 5 (8%) 













Pain + ECG = chest pain accompanied by electrocardiographic ST-T 
wave changes; PICA or CABG = percutaneous transluminal coronary 
angioplasty or coronary artery bypass grafting. 
gioplasty or bypass surgery for recurrent pain or compelling 
anatomic indications), or both, no significant difference was 
appreciated. 
There were no episodes of spontaneous major bleeding 
(Table 3). Eight patients experienced major bleeding, all 
related to a revascularization procedure; three patients 
(10%) were prior aspirin users and five (8%) were nonprior 
aspirin users. 
Discussion 
In the early 1980s the vast majority of patients with the 
acute coronary syndrome of unstable angina or non-Q wave 
myocardial infarction were not receiving any antithrombotic 
agent such as aspirin before hospital admission (1 ,3). In 
1988, Theroux eta!. (4) reported that about 19% of patients 
with unstable angina were already taking aspirin. By 1990 we 
(6) reported that > 30% of our study patients with either 
unstable angina or non-Q wave infarction had used aspirin 
before admission. Therefore, it has become important to 
describe in detail both the clinical and angiographic charac-
teristics of patients with an acute coronary syndrome al-
ready receiving antithrombotic therapy and their long-term 
follow-up. Do such patients constitute a high risk group with 
more extensive coronary disease? Is aspirin failure a marker 
for an increased thrombotic diathesis and a poorer long-term 
prognosis? 
Comparison with previous studies. To date, only one 
small study has compared patients with unstable angina who 
were prior aspirin users with nonprior aspirin users (10). 
Schreiber eta!. (10) compared 19 patients with aspirin failure 
with 12 nonusers of aspirin and observed a significant excess 
of three-vessel coronary disease in the aspirin failure group. 
However, during the brief 7-day follow-up study there was 
no difference in the proportion of patients in either group 
whose condition progressed to a major ischemic end point 
COHEN ET AL. 1461 
UNSTABLE ANGINA DURING ASPIRIN USE 
(21% vs. 25%). Our study represents a larger scale compar-
ison of patients with aspirin failure and nonprior users of 
aspirin and also provides more information on clinical out-
come and the need for intervention during a 3 month 
follow-up period. In the present study, as in the report of 
Schreiber et a!. (10), there were few epidemiologic differ-
ences between patients with aspirin failure and nonaspirin 
users. However, in contrast, to Schreiber eta!. (10), we did 
not observe any differences in the extent of coronary artery 
disease. This lack of difference in the "ischemic burden" 
between the two groups helps explain the lack of any 
difference in either the frequency of follow-up ischemic 
events or the rate of crossover to angioplasty or coronary 
bypass surgery between patients with aspirin failure and 
nonusers of aspirin. Finally, in contrast to two recent reports 
(ll, 12) describing an increased risk of bleeding after coro-
nary artery bypass surgery in prior aspirin users, we ob-
served very similar rates of major bleeding complications in 
both groups of patients. 
Mechanism of aspirin failure. The similarity between our 
patients with aspirin failure and nonaspirin users should not 
be interpreted as contradicting earlier trials, which show a 
beneficial effect of aspirin in unstable angina. There is no 
question that large scale, placebo-controlled therapeutic 
trials (I ,3-5) have established that antithrombotic therapy 
with aspirin in patients with unstable angina significantly 
reduces the number of subsequent myocardial infarctions 
and cardiac deaths. However, more recent trials (4,6), 
focusing on the subset of patients with angina at rest, have 
highlighted the significant number of patients who have 
unsuccessful aspirin therapy and experience recurrent myo-
cardial ischemia. 
What are the mechanisms of aspirin failure? Two groups 
of investigators (13-15) have focused on the effect of alpha-
adrenergic stimulation of aspirin-treated platelets. In these 
models administration of epinephrine (even though in larger 
than physiologic doses) overcame the inhibitory effect of 
aspirin and normalized the aggregatory response of platelets 
to injured vessel walls. In humans (16) aspirin was ineffec-
tive in preventing platelet activation and endothelial altera-
tion induced by cigarette smoking. Whether the effect of 
aspirin was overridden by nicotine or indirectly by an 
elevation in circulating catecholamines remains to be deter-
mined. 
Recent studies (17, 18) in an original ex vivo perfusion 
system used as a model for injured vessel wall-platelet 
interaction have delineated other mechanisms for aspirin 
failure. Using this model Badimon eta!. (17,18) highlighted 
the role of shear-induced cell activation; that is, platelet 
deposition significantly increased as percent stenosis in-
creased. Furthermore, although aspirin treatment did reduce 
platelet deposition in this model in the setting of a severe 
stenosis, it was not nearly as effective as blockers of the 
adhesive glycoprotein receptors found on the platelet sur-
face. Therefore, in patients with an acute coronary syn-
drome and severe stenosis, the platelet-inhibitory effects of 
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aspirin (mediated through the cyclooxygenase pathway) may 
be overcome by the platelet-stimulatory effect of local shear 
forces or by another potent platelet activator, the thrombin-
collagen pathway. · 
Limitations of the study. There are certain ljmitations to 
this study: 1) The clinical outcqmes we observed apply only 
when patients are treated, as ours were, with antithrombotic 
therapy soon after admission. 2) Cardiac catheterization was 
not performed op all patients and in some cases was per-
formed 4 or 5 days after admission. Although this delay may 
have influenced the findings of our morphologic analysis of 
the culprit l~sions, the recent study of Freeman et al. (19) 
suggested that complex lesion morphology in unstable an-
gina does not vary significantly with time. 3) Because the 
study group comprised only 93 patients, it is possible that the 
slightly lower (but not statistically significant) event rates in 
the prior aspirin group might be real if a larger sample size 
were studied. 
Clinical implications. Aspirin users experiencing angina 
at rest are similar to other patients with angina at rest. Even 
though they are "resistant" to aspjfiO· they are not at higher 
risk for cardiac events or requirement for revascularization. 
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